Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Collegium Pharmaceutical Inc    COLL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
10.13(c) 10.13(c) 10.05(c) 10.02(c) 9.81(c) Last
238 590 282 439 292 445 370 411 137 606 Volume
-1.07% 0.00% -0.79% -0.30% -2.10% Change
More quotes
Financials ($)
Sales 2017 31,5 M
EBIT 2017 -93,2 M
Net income 2017 -87,5 M
Debt 2017 -
Yield 2017 -
Sales 2018 84,2 M
EBIT 2018 -49,5 M
Net income 2018 -48,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 9,18x
Capi. / Sales2018 3,43x
Capitalization 289 M
More Financials
Company
Collegium Pharmaceutical, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products.These products target market opportunities through formulation based product improvements protected by intellectual property.It builds a... 
Sector
Pharmaceuticals
Calendar
05/16Earnings Release
More about the company
Surperformance© ratings of Collegium Pharmaceutical I
Trading Rating : Investor Rating :
More Ratings
Latest news on COLLEGIUM PHARMACEUTICAL I
04/20 Collegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference
04/04 COLLEGIUM PHARMACEUTICAL : Announces Appointment of Steven Passik, PhD, as Vice ..
04/03 Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicar..
03/30 COLLEGIUM PHARMACEUTICAL : Findings from E.A. Kopecky et al Has Provided New Inf..
03/28 Collegium to Present at the 16th Annual Needham Healthcare Conference
03/23 COLLEGIUM PHARMACEUTICAL : Patent Issued for Abuse-Deterrent Pharmaceutical Comp..
03/16 Collegium Announces Scientific Presentation at American Academy of Pain Medic..
03/13 COLLEGIUM PHARMACEUTICAL, INC : Entry into a Material Definitive Agreement, Fina..
03/10 COLLEGIUM PHARMACEUTICAL : Management's Discussion and Analysis of Financial Con..
03/09 COLLEGIUM PHARMACEUTICAL : posts 4Q loss
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/28Collegium Pharmaceutical Inc $COLL Stake Raised by State Street Corp  
04/26Want the latest upgrades & downgrades for $GEO $GEOI $UPL $COLL $RRR? Che.. 
04/20#TrendReversalUp $COLL COLLEGIUM PHARMACEUTICALS #TradeIdeas via ?  
04/19Collegium Pharmaceutical's buy rating reiterated at Needham & Company LLC.. 
04/11Possible bottom forming - $COLL chart  
More tweets
Qtime:12
News from SeekingAlpha
03/27 COLLEGIUM PHARMACEUTICAL : Modest Valuation Makes It Worthwhile To Monitor Xtamp..
03/24 Midday Gainers / Losers
03/13 Collegium Pharma inks $60M stock sale deal with Cantor
03/09 Collegium Pharmaceutical's (COLL) CEO Mike Heffernan on Q4 2016 Results - Ear..
03/09 Collegium Pharmaceutical beats by $0.05, misses on revenue
Advertisement
Chart COLLEGIUM PHARMACEUTICAL I
Duration : Period :
Collegium Pharmaceutical I Technical Analysis Chart | COLL | US19459J1043 | 4-Traders
Full-screen chart
Technical analysis trends COLLEGIUM PHARMAC...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 25,0 $
Spread / Average Target 155%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael Thomas Heffernan Chairman, President & Chief Executive Officer
Paul Brannelly Chief Financial Officer & Executive Vice President
Gino Santini Independent Director
David J. Hirsch Independent Director
John Gordon Freund Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COLLEGIUM PHARMACEUTIC..-36.99%289
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results